Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies

Medical Science Monitor

Volumn 9, Issue 2, 2003, Pages

  DiPaola, Robert S ^a,b   Rubin, Eric ^a,b   Toppmeyer, Deb ^a,b   Eid, Joseph ^b   Butzbach, Debarah ^b   Dvorzhinski, Dmitri ^b   Capanna, Terry ^b   Cairdella, Marie ^b   Shih, Joe W ^b,d   Goodin, Susan ^a,b,c   Todd, Mary B ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Bladder; Carboplatin; Gemcitabine; Paclitaxel; Transitional cell

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; UROTHELIUM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CELL SURVIVAL; COHORT STUDIES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0037298118     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Steinberg A, Trump D, Cummings K: Metastatic Bladder Cancer; Natural History, clinical course and consideration for treatment. Urologic Clinics of North America, 1992; 19: 735-746
2. Scher HI, Shipley WU, Herr HW: Cancer of the bladder, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology. PA, Lippincott-Raven, 1997; 1300-1322
3. Periolli R, Freidiani B, Manganelli A et al: Comparison between a cisplatin containing regimen and a carboplatin containing regimen for recurrent or metastatic bladder cancer patients. Cancer, 1996; 77: 344-351
4. Pronzato P, Landucci M, Vaira F et al: Carboplatin, methotrexate, vinblastine in out patients with advanced TCC of the bladder. American Journal of Clinical Oncology, 1995; 18: 223-225
5. Sternberg CN, Yagoda A, Socher HI: M-VAC for advanced transitional cell carcinoma of the urothelium. J Urol, 1988; 139: 461-469
6. Loehrer PJ, Einhorn LH, Elson PJ et al: A randomized comparison of cisplatin alone or in combination with methotexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol, 1992; 10: 1066-1073
7. Logothetis CJ, Dexeus FH, Finn L et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol, 1990; 8: 1050-1055
8. Saxman SB, Propert KJ, Einhorn LH et al: Long term follow up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol, 1997; 15: 2564-2569
9. Roth B, Dreicer R, Einhorn L et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A Phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 1994; 12: 2264-2270
10. Rangel C, Niell H, Miller A: Taxol and taxotere in bladder cancer. In vitro activity and urine stability. Cancer, Chemotherapy and Pharm, 1994; 33: 460-464
11. Vaughn DJ, Malkowicz SB, Zoltick B et al: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol, 1998; 16: 255-260
12. Boven E, Schipper AH, Erkeleus CAM et al: The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. British Journal of Cancer, 1993; 68: 52-56
13. Pollero CF, Ceribelli A, Grecco M et al: Weekly gemcitabine in advanced bladder cancer. A preliminary report from a phase I study. Ann Oncol, 1994; 5: 182-184
14. Von der Maase H, Hansen SW, Roberts JT et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results ofa large, randomized, multinational, multicenter phase III study. J Clin Oncol, 2000; 18: 3068-3077
15. Bellmunt J, Guillem V, Paz-Ares L et al: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol, 2000; 18: 3247-3255
16. Hussain M, Vaishampayan U, Du W et al: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol, 2001; 19: 2527-2533
17. Grem JL, Nguyen D, Monahan BP et al: Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol, 1999; 58: 477-486
18. Fujimoto S, Chikazawa H: Schedule-dependent and independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo. Jpn J Cancer Res, 1998; 89: 1343-1351